Xeris Biopharma Holdings, Inc.
XERS
$4.40
-$0.485-9.94%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.74% | 12.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.74% | 12.91% | |||
| Cost of Revenue | -30.27% | 74.49% | |||
| Gross Profit | 24.45% | 0.99% | |||
| SG&A Expenses | -24.31% | 12.44% | |||
| Depreciation & Amortization | 0.00% | 0.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.10% | 19.39% | |||
| Operating Income | 160.34% | -57.48% | |||
| Income Before Tax | 73.18% | -33.71% | |||
| Income Tax Expenses | 100.00% | -543.79% | |||
| Earnings from Continuing Operations | 67.51% | -4.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.51% | -4.89% | |||
| EBIT | 160.34% | -57.48% | |||
| EBITDA | 209.40% | -90.05% | |||
| EPS Basic | 67.52% | -4.45% | |||
| Normalized Basic EPS | 105.02% | -30.51% | |||
| EPS Diluted | 67.52% | -4.45% | |||
| Normalized Diluted EPS | 105.02% | -30.51% | |||
| Average Basic Shares Outstanding | 0.07% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
